Real-world outcomes of metastatic cancer patients hospitalized at initial diagnosis: ONIRIS, a national study

被引:0
作者
Vercueil, Colin [1 ,9 ]
Varnier, Romain [2 ,3 ]
Seban, Romain [4 ]
Ciaptacz, Lisa [5 ]
Pavillet, Julien [6 ]
Fraisse, Clea [7 ]
Darbas, Tiffany [5 ]
Abdallahoui, Safa [1 ,8 ]
Cox, David [1 ]
Martin, Sophie [1 ]
Trensz, Philippe [1 ]
Kurtz, Jean-Emmanuel [1 ]
Gantzer, Justine [1 ]
Ame, Shanti [1 ]
Bouleuc, Carole [4 ]
Chvetzoff, Gisele [2 ]
Eberst, Lauriane [1 ]
机构
[1] Inst Cancerol Strasbourg Europe, Dept Med Oncol, 17 Rue Albert Calmette, F-67200 Strasbourg, France
[2] Ctr Leon Berard, Dept Oncol Patient Support Care, 28 Prom Lea & Napoleon Bullukian, F-69008 Lyon, France
[3] Univ Claude Bernard Lyon 1, Res Healthcare Performance RESHAPE, INSERM, U12908, Ave Rockefeller, F-69008 Lyon, France
[4] Inst Curie, Dept Support & Palliat Care, 26 Rue Ulm, F-75005 Paris, France
[5] CHU Dupuytren, Dept Med Oncol, 2 Ave Martin Luther King, F-87000 Limoges, France
[6] CHU Grenoble Alpes, Dept Med Oncol, Blvd Chantourne Tronche, F-38700 Grenoble, France
[7] Ctr Georges Francois Leclerc, Dept Med Oncol, 1 Rue Prof Marion, F-21000 Dijon, France
[8] Hop Univ Strasbourg, Dept Med Intens Care, 1 Ave Moliere, F-67200 Strasbourg, France
[9] Inst Cancerol Strasbourg Europe, Dept Med oncol, 17 Rue Albert Calmette, F-67200 Strasbourg, France
关键词
Clinical oncology; Metastatic; Prognosis; Chemotherapy; Immunotherapy; Molecular targeted therapy; SURPRISE QUESTION;
D O I
10.1007/s00520-025-09202-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PurposeTherapeutic management of metastatic cancer patients who are hospitalized at the time of initial diagnosis because of impaired performance status and/or severe symptoms is challenging for clinicians. This study aims to describe their outcome. MethodsIn this prospective multicentric study, we included all adult, inpatients with newly diagnosed metastatic solid tumors between November 2021 and May 2022. Patients were followed for 3 months.. Our primary objective was to describe overall survival (OS). Secondary objectives included assessing SANT effectiveness in specific subgroups, identifying baseline factors associated with SANT initiation, and assessing usual prognostic tools and factors associated with response.Results107 patients were included. Seventy-four (69%) initiated a SANT. Among them, 39 patients were alive at 3 months. Median overall survival was 1.7 months for the entire cohort. Thirty-seven patients (55%) died in the unit where they were first admitted. Patients with chemo-sensitive tumors, such as testicular non-seminomatous germ cell tumors (100% OS at 3 months), or those receiving targeted therapies or hormone therapies (80% OS at 3 months), showed numerically better outcomes. Factors associated with the initiation of a SANT were young age (OR = 0,94 [0,90; 0,98]), low Charlson Comorbidity Index (OR = 0,56 [0,42; 0,73]), and patient's or caregiver's request for treatment (respectively, OR = 0,07 [0,02; 0,17] and 0,17 [0,06; 0,42], compared to the respective reference category (no request)).ConclusionMetastatic cancer patients hospitalized at the time of diagnosis share a similar poor survival. Despite the notable exception of chemo-sensitive tumors and specific molecular alterations, the high mortality observed in both groups suggests that SANT has a limited impact on their outcomes. Best supportive care can be reasonably considered for these patients. The benefit of SANT in this altered population should be assessed in larger prospective studies.
引用
收藏
页数:12
相关论文
共 34 条
  • [31] Systemic Therapy Decision Making in Advanced Cancer: A Qualitative Analysis of Patient-Oncologist Encounters
    Wasp, Garrett T.
    Knutzen, Kristin E.
    Murray, Genevra F.
    Brody-Bizar, Olivia C.
    Liu, Matthew A.
    Pollak, Kathryn, I
    Tulsky, James A.
    Schenker, Yael
    Barnato, Amber E.
    [J]. JCO ONCOLOGY PRACTICE, 2022, 18 (08) : 598 - +
  • [32] Immune Checkpoint Inhibitors
    West, Howard
    [J]. JAMA ONCOLOGY, 2015, 1 (01) : 115 - 115
  • [33] YATES JW, 1980, CANCER-AM CANCER SOC, V45, P2220, DOI 10.1002/1097-0142(19800415)45:8<2220::AID-CNCR2820450835>3.0.CO
  • [34] 2-Q